News Archive

April 2020

• Key ReleaseApr 28, 2020

  Novartis setzt im 1. Quartal die starke operative Performance fort, bestätigt derzeit die Prognose 2020 und fördert verschiedenste Aktivitäten, um globale Massnahmen gegen COVID-19 zu unterstützen

  Der Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt im ersten Quartal 2020 um 13% (kWk2, +11% USD) mit zweistelligen Zuwächsen (kWk) bei Innovative Medicines und Sandoz: Zu den…
• Key ReleaseApr 28, 2020

  Novartis conserve une forte performance opérationnelle au 1er trimestre, confirme à ce stade les prévisions pour 2020 et fournit de grands efforts pour contribuer à la réponse mondiale au Covid-19

  Au 1er trimestre 2020, chiffre d’affaires net des activités poursuivies1 en hausse de 13% (tcc2, +11% USD) avec une croissance à deux chiffres (tcc) d’Innovative Medicines et de Sandoz: Les…
• 
  StoryApr 24, 2020 From Our Labs

  A visual tour of scientific strategies for combating coronavirus

  Researchers around the world are collaborating to provide solutions to immediate and future challenges.

• StatementApr 23, 2020

  Novartis announces flexible return to office and on-site field activities, starting May 11, 2020
• Media ReleaseApr 22, 2020

  Novartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease

  Data from Phase III REACH2 study, published in The New England Journal of Medicine, demonstrate Jakavi can improve outcomes for patients with acute graft-versus-host disease (GvHD) who do not respond…
• Media ReleaseApr 22, 2020

  Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma

  If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults…
• Media ReleaseApr 21, 2020

  AveXis Community Statement on the Coronavirus Disease (COVID-19)

  Dear SMA Community, Like many organizations across the United States and around the world, AveXis is closely monitoring the coronavirus disease (COVID-19) and its impact on patients, the SMA…
• Media ReleaseApr 21, 2020

  Novartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)

  New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent® (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed…
• Featured NewsApr 20, 2020

  World Malaria Day 2020

  This year, World Malaria Day is happening as countries around the world are fighting the COVID-19 pandemic.

• 
  StoryApr 20, 2020 People and Culture

  Going the extra mile to keep clinical trials on track during the COVID-19 pandemic

  A Novartis team couriers an experimental treatment across Europe to a patient as transit grinds to a halt.

• Media ReleaseApr 20, 2020

  Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients

  Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease Trial…
• Media ReleaseApr 20, 2020

  Novartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye”

  Technology has potential to reimagine treatment for amblyopia (“lazy eye”), a leading cause of vision loss in children and young adults1Acquisition expands the Novartis refractive disorder pipeline…